Group 1 - The pharmaceutical sector in Hong Kong is experiencing a strong rally, with notable gains in stocks such as Kailaiying, which rose over 14%, and Sangfor Pharmaceuticals, which increased by 7.6% [1][2] - Sangfor Pharmaceuticals announced a licensing agreement with Pfizer, receiving an upfront payment of $1.25 billion, which significantly boosted investor confidence [1] - The China National Medical Products Administration has accepted a new drug application for cyclosporine eye gel from Zhaoke Ophthalmology, indicating positive regulatory developments in the industry [1] Group 2 - Longcheng Securities expressed optimism about the pharmaceutical sector, citing frequent favorable policies that are expected to lead to a steady recovery in industry sentiment [1] - Morgan Stanley's research report maintains a positive outlook on the Chinese pharmaceutical industry, highlighting supportive policies for innovation and low dependency on U.S. exports, which mitigates risks from geopolitical tensions and uncertainties in U.S. drug pricing [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 行政總裁之變動 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」）董 事（「董 事」）會（「董事會」）欣 然 宣 佈 本 公 司 行 政 總 裁（「行政總裁」）的 以 下 變 動： 行政總裁之變動 隨 着 本 公 司 業 務 規 模 擴 大 及 考 慮 下 一 步 公 司 發 展 需 要，吳 鐵 先 生（「吳先生」）希 望 投 放 更 多 時 間 專 注 於 本 集 團 的 發 展 戰 略 等 事 宜，故 此 已 辭 任 行 政 總 裁 職 務， 自2025年5月19日 起 生 效。吳 先 生 將 繼 續 擔 任 董 事 會 主 席 兼 執 行 董 事。吳 先 生 及 董 事 會 確 認，吳 先 生 與 董 事 會 之 ...

Company News - TaiLing Pharmaceutical (01011.HK) proposed to split the assets of its joint venture company while ensuring the protection of all shareholders' rights, dissolving the joint venture relationship for independent operations [2] - China Evergrande (03333.HK) has filed a joint application with the liquidators of CEG Holdings to the Hong Kong court on May 12 [2] - Yanzhou Coal Mining (01171.HK) plans to invest approximately $300 million in cash to acquire shares of Highland Resources, becoming its largest shareholder [2] - Baolong Properties (01238.HK) has postponed the hearing for its liquidation application to July 21 [2] - Sunny Optical Technology (02382.HK) reported a smartphone lens shipment of 103 million units in April, a month-on-month increase of 9.2% and a year-on-year increase of 1.3%; vehicle lens shipments reached 11.566 million units, with a month-on-month increase of 17.8% and a year-on-year increase of 28.9%, driven by increased customer demand and improved product structure [2] Industry News - CK Hutchison (00001.HK) issued a statement regarding port transactions, asserting that it will never engage in any illegal or non-compliant activities [3] - Contemporary Amperex Technology (CATL) saw its Hong Kong public offering portion oversubscribed by 21 times, attracting HKD 51.7 billion in financing subscriptions [3] - Kweichow Moutai has no current plans for a Hong Kong listing [3] - China Merchants Securities (06099.HK) announced the resignation of Vice President Zhang Haochuan due to personal reasons, effective May 12, 2025 [3] - Rongchang Biopharmaceutical (09995.HK) received a notice of acceptance for its clinical trial application for the antibody-drug conjugate RC278 [3] - China CNR Corporation (01766.HK) and its subsidiaries have recently signed several major contracts worth approximately CNY 54.74 billion [3]

自願公告 本 公 告 乃 由 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出。本 公 司 董 事（「董 事」）會（「董事會」）謹 此 就 潛 在 意 向 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 最 新 資 料。 可能進行之收購及出售事項 董 事 會 收 到 北 京 康 辰 生 物 科 技 有 限 公 司（「聯營公司」）及 其 大 股 東 北 京 康 辰 藥 業 股 份 有 限 公 司（「康辰藥業」）一 家 在 上 海 交 易 所 主 板 上 市 的 公 司（股 票 編 號： 603590）通 知，康 辰 藥 業 主 動 提 出 在 保 護 所 有 股 東 權 益 的 基 礎 上 對 聯 營 公 司 之 資 產 進 行 拆 分，解 散 聯 營 關 係，各 自 獨 立 經 營。 具 體 內 容 如 下： 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容而產生或因 ...

自願公告 本 公 告 乃 由 中 國 泰 凌 醫 藥 集 團 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）自 願 作 出。本 公 司 董 事（「董 事」）會（「董事會」）謹 此 向 本 公 司 股 東 及 潛 在 投 資 者 欣 然 宣 佈 本 集 團 對 聯 營 公 司 業 績 承 諾 已 經 達 成。 有關聯營公司業績承諾達成 本 公 司 收 到 聯 營 公 司 北 京 康 辰 生 物 科 技 有 限 公 司（「聯營公司」）及 其 大 股 東 北 京 康 辰 藥 業 股 份 有 限 公 司（「康辰藥業」）一 家 在 上 海 交 易 所 主 板 上 市 的 公 司（股 票 編 號：603590）通 知，以 及 其 發 出 的 業 績 承 諾 期 公 告： 2020年4月21日，康 辰 藥 業、聯 營 公 司 與 本 公 司、泰 凌 醫 藥 國 際 有 限 公 司（「泰 凌 國 際」）、泰 凌 醫 藥（香 港）有 限 公 司、泰 凌 醫 藥（海 外）控 股 有 限 公 司、泰 凌 醫 藥（亞 洲）有 限 公 司（「泰凌亞洲」）、蘇 州 第 壹 製 藥 有 限 公 司 及 本 ...

China NT Pharma Group Company Limited 中國泰凌醫藥集團有限公司 (incorporated in Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） NOTIFICATION LETTER 通知信函 30 April 2025 Dear Non-registered Holder(s)(Note 1) , China NT Pharma Group Company Limited (the "Company") – Notification of publication of Annual Report 2024, Circular dated 30 April 2025 and Notice of Annual General Meeting (the "Current Corporate Communication") (Stock Code 股份代號 : 1011) The English and Chinese versions of the Company's Current Corporate Com ...

China NT Pharma Group Company Limited 中國泰凌醫藥集團有限公司 (incorporated in Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號 : 1011) NOTIFICATION LETTER 通知信函 If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communication and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's branch share r ...

茲通告中國泰凌醫藥集團有限公司（「本公司」）謹訂於二零二五年六月三十日（星期一）上午 十一時正假座香港干諾道中168–200號信德中心西座21樓2102室舉行股東週年大會（「股東週年大 會」），藉以處理下列事項： 不提供茶點、食物或飲料，也不提供任何公司禮品、禮券或餅券。 普通決議案 – 1 – 香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不會就本通告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 股東週年大會通告 「有關期間」指自通過本決議案直至下列兩者中較早發生者之期間： 承董事會命 中國泰凌醫藥集團有限公司 主席 吳鐵 1. 省覽並採納截至二零二四年十二月三十一日止年度之本公司經審核綜合財務報表以 及董事會及核數師報告。 2. (a) 重選本公司之下列退任董事： (i) 吳鐵先生為執行董事 (ii) 吳銘軍先生為獨立非執行董事 (b) 授權董事會釐定本公司董事薪酬。 3. 考慮重新委任大華馬施雲會計師事務所有限公司為本公司核數師，並授權本公司董 事 ...

此乃要件 請即處理 閣下如對本通函任何方面或應採取的任何行動有任何疑問，應諮詢 閣下的股票經紀或其他註冊證券 商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已將名下的中國泰凌醫藥集團有限公司股份全部售出或轉讓，應立即將本通函連同隨附的代表 委任表格送交買主或承讓人或經手買賣或轉讓的銀行、股票經紀或其他代理商，以便轉交買主或承讓 人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本通函全部或任何部份內容而產生或因倚賴該等內容而 引致的任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：1011） 建議授出發行股份及 購回股份的一般授權、 建議重選退任董事、 及 股東週年大會通告 ***不提供茶點、食物或飲料，也不提供任何公司禮品、禮券或餅券。*** 中國泰凌醫藥集團有限公司謹訂於二零二五年六月三十日（星期一）上午十一時正假座香港干諾道中 168–200號信德中心西座21樓2102室舉行股東週年大會，大會通告載於本通函第12頁至第16頁。隨 函附奉股東週年大會適用的代表委任表格。該代表委任表格亦刊載於香 ...

Financial Performance - The overall revenue for the year ended December 31, 2024, increased by RMB 30.6 million or 413.5% to RMB 38.0 million compared to RMB 7.4 million in the previous year[8]. - The net loss for the year ended December 31, 2024, was RMB 53.4 million, a decrease of 62.8% from a net loss of RMB 143.6 million in the same period of 2023[8]. - Revenue from digital services and sales agency fees increased by RMB 30.6 million or 413.5% to RMB 38.0 million, primarily due to the new digital services segment starting in 2024[16]. - The cost of sales for the year ending December 31, 2024, was approximately RMB 32.7 million, resulting in a gross profit of about RMB 5.3 million, a decrease of approximately RMB 2.1 million or 28.4% compared to the previous year[17]. - The total comprehensive loss attributable to owners of the company from continuing operations was RMB 53.4 million, compared to RMB 33.5 million in the previous year, with basic and diluted loss per share at RMB 20.20[20]. - Total debt as of December 31, 2024, was RMB 552.96 million, up from RMB 515.66 million in 2023, with a net debt of RMB 543.34 million[25]. - The debt-to-asset ratio increased to 165.52% in 2024 from 156.68% in 2023, indicating a higher leverage position[30]. - The company recorded a net loss from continuing operations of approximately RMB 53.4 million for the year ended December 31, 2024, compared to a net loss of approximately RMB 33.5 million in the previous year[12]. Business Model and Strategy - The company has transitioned from a heavy asset business model to a light asset model, focusing on cost control and improving financial conditions[12]. - The company plans to launch its "AI + Medical Industry" transformation in 2025, establishing new departments in China to support comprehensive medical services[13]. - The company has successfully created the "Faimeng - Smart Medical Health Management" brand, establishing a unique position in the market as the only provider of a complete smart health management ecosystem[7]. - The company aims to develop a comprehensive health platform focusing on orthopedic diseases, including drug supply, rehabilitation management, and digital medical services[11]. - The company is leveraging artificial intelligence to create personalized medical solutions to meet the growing patient demand[13]. - The company has transformed into a light-asset operation focusing on "AI + healthcare," with major business segments including OEM production, agency sales of medical products, and digital healthcare services[14]. Corporate Governance - The board consists of two executive directors, two non-executive directors, and three independent non-executive directors, with independent non-executive directors making up 43% of the board[45]. - The company has adopted the corporate governance code as per the Hong Kong Stock Exchange listing rules and has complied with all applicable provisions for the year ending December 31, 2024, except for the separation of roles between the chairman and CEO[64]. - The board has established procedures to ensure that the selection and nomination of board candidates consider a wide range of backgrounds and experiences[73]. - The board of directors held four regular meetings in 2023, with a 100% attendance rate for all members[78]. - The audit committee reviewed the group's internal controls, risk management, and financial reporting, including the annual results for the year ending December 31, 2023[87]. - The company has received annual confirmations of independence from all current independent non-executive directors, affirming their ability to make independent judgments[67]. Employee and Labor Practices - The total number of full-time employees increased to 22 as of December 31, 2024, compared to 16 in 2023[43]. - Total compensation, benefits, and social security costs amounted to RMB 6.1 million for the year ended December 31, 2024, up from RMB 3.6 million in 2023[43]. - Employee turnover rate for the fiscal year 2024 is 9.09%, down from 12.5% in 2023, with 2 employees leaving in both years[167]. - The company adheres to a comprehensive compensation system, ensuring fair and reasonable salaries and rewards for employees[161]. - The company has a strict policy against discrimination in hiring, compensation, training, and promotion based on race, religion, gender, and other factors[162]. - The company emphasizes employee health and safety, implementing policies to prevent occupational hazards and risks[170]. Environmental, Social, and Governance (ESG) Initiatives - The environmental, social, and governance (ESG) report outlines the company's initiatives and performance for the fiscal year ending December 31, 2024[128]. - The ESG report includes a commitment to sustainable development and highlights the importance of stakeholder engagement in identifying significant issues[135]. - The company plans to expand its ESG reporting scope to include offices in Hainan and Beijing for the 2024 report[129]. - The company has established a governance framework to integrate sustainability principles into daily management and operations[133]. - The company emphasizes the importance of stakeholder feedback in its sustainability efforts, addressing concerns related to product quality and environmental management[135]. - The company has implemented measures to reduce energy consumption, including shutting down idle appliances and replacing old equipment with more energy-efficient models[150]. Financial Management and Liquidity - The company is actively negotiating to obtain new financing sources to repay overdue borrowings[53]. - The board believes that the company will have sufficient operating funds to meet financial obligations due in the next 12 months[52]. - The company has not purchased, sold, or redeemed any of its listed securities during the year ended December 31, 2024[44]. - The company has adopted a dividend policy to maintain sufficient cash reserves for operational needs and future business growth[123]. - The company is preparing to launch an AI-based bone density detection product in 2025, expanding its product offerings in the healthcare sector[14]. Risk Management - The company faces significant uncertainties regarding its ability to continue as a going concern due to various factors, including the need for new financing sources[114]. - The board is responsible for maintaining an effective risk management and internal control system, which is reviewed annually[101]. - The company has established a code of conduct to define ethical standards for all employees[101]. - The company is engaged in a competitive market environment, which may lead to decreased sales, price reductions, and loss of market share[106]. Community Engagement and Corporate Social Responsibility - The company emphasizes community investment, encouraging employees to participate in charitable activities and fundraising initiatives[191]. - The company is committed to corporate social responsibility, actively participating in community activities to foster a positive corporate culture[191]. - The company plans to enhance its community engagement efforts to further contribute to societal well-being[191].